| |
All Patients n (%)
|
Groups
|
|---|
| | | | |
A (n = 84)
| |
B (n = 114)
| | |
|---|
| | Bad (GOS≦3) |
Good (GOS > 3)
|
P
| Bad (GOS≦3) |
Good (GOS > 3)
|
Total
| Bad (GOS≦3) |
Good (GOS > 3)
|
Total
|
P
|
|---|
| |
145 (73.2)
|
53 (26.8)
| |
51 (60.7)
|
33 (39.3)
|
84
|
94 (82.5)
|
20 (17.5)
|
114
|
0.001
|
|
Age
| | | | | | | | | |
0.001
|
| ≦60 |
85 (65.4)
|
45 (34.6)
|
0.001
|
18 (40.0)
|
27 (60.0)
|
45
|
67 (78.8)
|
18 (21.2)
|
85
|
<0.001
|
|
> 60
|
60 (88.2)
|
8 (11.8)
|
33 (84.6)
|
6 (15.4)
|
39
|
27 (93.1)
|
2 (6.9)
|
29
|
0.451
|
|
Gender
| | | | | | | | | |
0.001
|
|
Female
|
40 (74.1)
|
14 (25.9)
|
0.870
|
15 (68.2)
|
7 (31.8)
|
22
|
25 (78.1)
|
7 (21.9)
|
32
|
0.417
|
|
Male
|
105 (72.9)
|
39 (27.1)
|
36 (58.1)
|
26 (41.9)
|
62
|
69 (84.1)
|
13 (15.9)
|
82
|
0.001
|
|
Diabetes
| | | | | | | | | |
0.001
|
|
No
|
85 (66.9)
|
42 (33.1)
|
0.008
|
32 (53.3)
|
28 (46.7)
|
60
|
53 (79.1)
|
14 (20.9)
|
67
|
0.002
|
|
Yes
|
60 (84.5)
|
11 (15.5)
|
19 (79.2)
|
5 (20.8)
|
24
|
41 (87.2)
|
6 (12.8)
|
47
|
0.490
|
|
GCS
| | |
<0.001
| | | | | | |
0.004
|
|
15-13 (grade 1)
|
14 (46.7)
|
17 (53.3)
| |
5 (29.4)
|
12 (70.6)
|
17
|
9 (69.2)
|
4 (30.8)
|
13
|
0.033
|
|
12-7 (grade 2)
|
55 (62.5)
|
33 (37.5)
|
0.130a
|
18 (48.6)
|
19 (51.4)
|
37
|
37 (72.5)
|
14 (27.5)
|
51
|
0.023
|
|
6-3 (grade 3)
|
76 (95.0)
|
4 (5.0)
|
<0.001b
|
28 (93.3)
|
2 (6.7)
|
30
|
48 (96.0)
|
2 (4.0)
|
50
|
0.705
|
|
NIHSS
| | |
<0.001
| | | | | | |
0.001
|
|
<15 (grade 1)
|
15 (46.9)
|
17 (53.1)
| |
4 (23.5)
|
13 (76.5)
|
17
|
11 (73.3)
|
4 (26.7)
|
15
|
0.006
|
|
15-20 (grade 2)
|
28 (56.0)
|
22 (44.0)
|
0.422a
|
10 (45.5)
|
12 (54.5)
|
22
|
18 (64.3)
|
10 (35.7)
|
28
|
0.187
|
|
>20 (grade 3)
|
102 (87.9)
|
14 (12.1)
|
<0.001b
|
37 (82.2)
|
8 (17.8)
|
45
|
65 (91.5)
|
6 (8.5)
|
71
|
0.135
|
|
HV , mL
| | | | | | | | | |
0.001
|
| ≦60 |
80 (61.1)
|
51 (38.9)
|
<0.001
|
29 (47.5)
|
32 (52.5)
|
61
|
51 (72.9)
|
19 (27.1)
|
70
|
0.003
|
|
> 60
|
65 (97.0)
|
2 (3.0)
|
22 (95.7)
|
1 (4.3)
|
23
|
43 (97.7)
|
1 (2.3)
|
44
|
1.000
|
|
IVH
| | |
<0.001
| | | | | | |
0.001
|
|
0
|
31 (48.4)
|
32 (51.6)
| |
10 (33.3)
|
20 (66.7)
|
30
|
21 (61.8)
|
13 (38.2)
|
34
|
0.024
|
|
1-4 (grade 1)
|
43 (69.4)
|
19 (30.6)
|
0.018c
|
14 (51.9)
|
13 (48.1)
|
27
|
29 (82.9)
|
6(17.1)
|
35
|
0.009
|
|
5-8 (grade 2)
|
36 (100.0)
|
0
|
<0.001a
|
15 (100.0)
|
0
|
15
|
21 (100.0)
|
0
|
21
|
1.000
|
|
9-12 (grade 3)
|
35 (97.2)
|
1 (2.8)
|
1.000
|
12 (100.0)
|
0
|
12
|
23 (95.8)
|
1 (4.2)
|
24
|
1.000
|
|
Complications, n (%)
| | | | | | | | | |
|
RB
| | | | | | | | | |
0.001
|
|
No
|
136 (72.0)
|
53 (28.0)
|
0.116
|
50 (60.2)
|
33 (39.8)
|
83
|
86 (81.1)
|
20 (18.9)
|
106
|
0.002
|
|
Yes
|
9 (100.0)
|
0
|
1 (100.0)
|
0
|
1
|
8 (100)
|
0
|
8
|
1.000
|
|
RF
| | | | | | | | | |
0.001
|
|
NO
|
124 (70.1)
|
53 (29.9)
|
0.003
|
46 (58.2)
|
33 (41.8)
|
79
|
78 (79.6)
|
20 (20.4)
|
98
|
0.002
|
|
Yes
|
21 (100.0)
|
0
|
5 (100.0)
|
0
|
5
|
16 (100.0)
|
0
|
16
|
1.000
|
|
PI
| | | | | | | | | |
0.001
|
|
No
|
70 (60.3)
|
46 (39.7)
|
<0.001
|
22 (44.0)
|
28 (56.0)
|
50
|
48 (72.7)
|
18 (27.3)
|
66
|
0.002
|
|
Yes
|
75 (91.5)
|
7 (8.5)
|
29 (85.3)
|
5 (14.7)
|
34
|
46 (95.8)
|
2 (4.2)
|
48
|
0.120
|
|
UGB
| | | | | | | | |
0.001
|
|
No
|
131 (71.6)
|
52 (28.4)
|
0.075
|
44 (57.1)
|
33 (42.9)
|
77
|
87 (82.1)
|
19 (17.9)
|
106
|
<0.001
|
|
Yes
|
14 (93.3)
|
1 (6.7)
|
7 (100.0)
|
0
|
7
|
7 (87.5)
|
1 (12.5)
|
8
|
1.000
|
- P values were calculated using the Wilcoxon or Kruskal-Wallis rank sum tests. Groups: A, minimal invasive puncture and drainage; B, decompressive craniectomy; GOS: Glasgow Outcome Scale; BP: blood pressure; SPB systolic blood pressure. DBP: diastolic blood pressure. GCS: Glasgow Coma Scale; NIHSS: National Institutes of Health Stroke Scale; HV: hematoma volume; IVH: intraventricular hemorrhage; RB: rebleed; PI: pulmonary infection; RF: renal failure; UGB: upper gastrointestinal bleeding; agrade 1 vs. grade 2; bgrade 2 vs. grade 3; cIVH 0 vs. IVH grade 1.
